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Abstract
Background: Effective and stable knockdown of multiple gene targets by RNA interference is
often necessary to overcome isoform redundancy, but it remains a technical challenge when
working with intractable cell systems.
Results:  We have developed a flexible platform using RNA polymerase II promoter-driven
expression of microRNA-like short hairpin RNAs which permits robust depletion of multiple target
genes from a single transcript. Recombination-based subcloning permits expression of multi-
shRNA transcripts from a comprehensive range of plasmid or viral vectors. Retroviral delivery of
transcripts targeting isoforms of cAMP-dependent protein kinase in the RAW264.7 murine
macrophage cell line emphasizes the utility of this approach and provides insight to cAMP-
dependent transcription.
Conclusion: We demonstrate functional consequences of depleting multiple endogenous target
genes using miR-shRNAs, and highlight the versatility of the described vector platform for multiple
target gene knockdown in mammalian cells.
Background
The discovery of RNA interference (RNAi) and its use as an
experimental tool has heralded a new era in functional
genomics [1,2]. The ability of short interfering RNA
(siRNA) to perturb expression of any gene target high-
lights the enormous potential of this technique. However,
siRNA delivery into primary cells, cell lines that are diffi-
cult to transfect and delivery to specific cell types in vivo
remains a key technical issue.
A variety of vector-based approaches, which express siR-
NAs as short hairpin (sh)RNAs, have been developed to
permit delivery through viral vectors [3]. Designing such
shRNA in the context of a naturally occurring RNA
polymerase (pol) II-driven microRNA transcript (miR-
shRNA; Fig. 1a) increases the flexibility of this approach
allowing for conditional and cell type-specific expression
[4-11]. The observation that some endogenous microR-
NAs (miRNA) are processed from single transcripts con-
taining multiple primary miRNA sequences [12,13] adds
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Expression of concatenated miR30-based shRNAs in a single transcript can promote efficient knockdown of at least three tar- get genes Figure 1
Expression of concatenated miR30-based shRNAs in a single transcript can promote efficient knockdown of at 
least three target genes. (a) Predicted secondary structure of the unprocessed miR30 transcript. Arrow depicts the loca-
tion of the mature miRNA which is replaced with gene specific siRNA sequence in the expressed miR-shRNA. (b) Proposed 
structure of a transcript expressing multiple gene specific miR-shRNAs. (c) Subcloning scheme for creation of multi-miR-
shRNA transcripts. Prom; any of the pol II promoters listed in Fig. 2a, attL1 + attL2; Gateway recombination sites, 5'miR + 
3'miR; flanking sequence derived from human miR30. (d) Single CMV promoter-driven miR-shRNAs against arrestin 2 (Arr2), 
G beta 2 (Gβ2) and G-protein coupled receptor kinase 2 (Grk2) promote potent and specific knockdown when co-expressed 
with YFP-tagged cDNAs of their respective target genes in HEK293 cells. (e) Single transcripts expressing different combina-
tions of double miR-shRNAs promote efficient dual target knockdown. (f) A single transcript expressing miR-shRNA against 
Arr2, Gβ2 and Grk2 retains potency against all three target genes.BMC Molecular Biology 2007, 8:98 http://www.biomedcentral.com/1471-2199/8/98
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to the potential experimental utility of this approach to
RNAi. In using RNAi as an experimental tool, the ability
to effectively deplete multiple gene targets is vital to
address the issue of isoform redundancy, especially in
mammalian cell systems. Thus, a flexible vector platform
that allows for effective multi-gene knockdown in essen-
tially any cell system would be of great value.
We report the development of a versatile system which
permits the knockdown of multiple target genes from a
single transcript, and we show efficient depletion of
endogenous pairs of signaling genes in the RAW264.7
murine macrophage-like cell line. Importantly, we dem-
onstrate the absolute requirement for multi-gene deple-
tion to observe phenotypes in processes dependent on
proteins with redundant isoforms.
Results and discussion
To determine if multi-miR-shRNA transcripts could pro-
mote efficient and specific knockdown in mammalian
cells, we first created plasmids expressing potent miR-shR-
NAs against the murine orthologs of three genes involved
in G-protein signaling: arrestin 2 (Arr2), G-protein cou-
pled receptor kinase 2 (Grk2) and G-protein beta 2 (Gβ2)
(see methods and Fig. 2a). Co-transfection of each of
these miR-shRNA-expressing plasmids with YFP-tagged
cDNAs of all three target genes in HEK293 cells resulted in
potent and specific knockdown of the intended target pro-
tein (Fig. 1d). Using the premise that multiple miR-shR-
NAs targeting different genes could be linked in a single
transcript (Fig. 1b), we designed our miR-shRNA-express-
ing plasmids to allow simple concatenation through
directional subcloning (Fig. 1c). Using this strategy, we
created dual miR-shRNA constructs targeting Arr2+Gβ2,
Grk2+Arr2 and Grk2+Gβ2. Co-transfection with YFP-
tagged cDNAs of the target genes in HEK293 cells resulted
in specific knockdown of each target gene pair, with no
apparent loss of shRNA potency (Fig. 1e). Similarly, a con-
struct expressing all three miR-shRNAs led to efficient tri-
ple target knockdown (Fig. 1f). To determine if plasmids
with multiple miR-shRNAs remain stable in E.coli, we per-
formed serial passaging of the triple miR-shRNA construct
used in Fig. 1f. Sequencing of clones isolated from up to
five rounds of serial passaging found no re-arrangement
of miR-shRNA sequences (data not shown). The data in
Figure 1 validate the principle of depleting multiple gene
targets with a single transcript containing multiple miR-
shRNA cassettes, however, such transient expression in a
readily transfectable cell line offers little practical utility
over the use of multiple siRNAs.
To determine if this shRNA expression approach could be
applied to less tractable cells, we created a comprehensive
range of viral vectors to which miR-shRNA cassettes could
be transferred by Gateway® recombination (Additional file
1). Using a retroviral vector which bicistronically
expresses the miR-shRNA(s) with a neomycin resistance
gene (Fig. 3a), we created stable lines of RAW264.7
murine macrophage (RAW) cells expressing single and
dual miR-shRNAs against three different pairs of signaling
genes; Arr2 and 3, Grk2 and 5 and the cAMP-dependent
protein kinase (Pka) catalytic subunits Cα and Cβ. We
observed efficient single and dual knockdown of the
endogenous target genes in RAW cells using this approach
(Fig. 3b–e). These data demonstrate the flexibility of the
multi-miR-shRNA approach in effectively targeting three
different pairs of signaling genes in a cell line which is
intractable to efficient siRNA transfection. Moreover, the
ability to deplete multiple genes with redundant func-
tions is an important technical advance in the effort to dis-
sect signaling pathways in cells such as RAW macrophages
[14].
Mammalian cells express two Pka catalytic subunits, Cα
and Cβ. Mice are viable after knockout of either gene, sug-
gesting that either isoform can perform the required phys-
iological functions of this kinase [15,16]. To determine
the functional consequences of depleting both of the Pka
C subunits in RAW cells, we assessed the cAMP-induced
phosphorylation of the vasodilator stimulated phospho-
proteins (VASP), a known substrate of Pka [17]. In
response to cAMP analogs, we observed a significant
increase in phospho-VASP, which was unaffected in cells
depleted of either Pka Cα or Pka Cβ (Fig. 4a). However, in
cells with both Cα and Cβ knocked down, there was
almost complete attenuation of VASP phosphorylation in
response to cAMP (Fig. 4a). It is well established that Pka
mediates many transcriptional effects, primarily through
phosphorylation and activation of cAMP response ele-
ment (CRE) binding protein (CREB) and cAMP response
element modulator (CREM) [18]. Based on a recent
microarray study in RAW cells [19], we identified several
cAMP-dependent mRNAs and selected four targets for
assessment in our Pka knockdown cell lines; Nr4a1,
Nr4a2, Ctla2α and Ctla2β. Nr4a1/Nur77 and Nr4a2/
Nurr1, members of the NR4A subfamily of orphan
nuclear receptors, are potential transcriptional mediators
in many cell types and have been shown to be regulated
by cAMP [20]. Regulation of the transcription of Ctla2α
and Ctla2β, cysteine protease inhibitors originally identi-
fied in cytotoxic T lymphocytes [21], has not been
reported previously. None of these cAMP-dependent tran-
scripts show any significant alteration of 8pCPT-cAMP
induced increase in cells depleted for either Pka catalytic
subunit, whereas depletion of both Pka Cα and Cβ leads
to a marked decrease in transcript induction (Fig. 4b–e).
These data provide the first evidence that Ctla2 transcrip-
tion is PKA-dependent. More importantly, our data dem-
onstrate the value of an RNAi platform which permits the
depletion of multiple endogenous gene targets from a sin-BMC Molecular Biology 2007, 8:98 http://www.biomedcentral.com/1471-2199/8/98
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gle viral infection of an intractable cell line. The system
allows the demonstration of downstream biological con-
sequences of the loss of a function redundantly performed
by related proteins. Only upon effective depletion of both
Pka C subunits is a phenotype observed (Fig. 4). There are
numerous examples, especially in G-protein mediated sig-
naling pathways, where mammalian cells express multi-
ple proteins with redundant function, presumably to
build robustness into the system. It is therefore notewor-
thy that the cells maintain a small degree of response in
the recorded readouts in the dual knockdown cells (Fig.
4). Although this result could argue that an alternative
Entry vector design and miR-shRNA cloning strategy Figure 2
Entry vector design and miR-shRNA cloning strategy. (A) Schematic showing the architecture of entry vectors for 
miR-shRNA cloning. Vectors were created with five different promoter options; CMV, EF1, β-actin, Ubiquitin-c and MSCV 
LTR. Single letters denote the following restriction enzyme sites: D; DpaI, B; BamHI, S; SpeI, M; MfeI, X; XbaI, P; PstI. These 
sites are unique apart from the exceptions noted below the figure. The ccdB is a counterselection gene toxic to most E.coli 
strains, which reduces parent vector background when cloning shRNAs. (B) Sequence details around the shRNA cloning sites 
demonstrate alternative methods of shRNA insertion into an entry vector. For shRNAs cloned as BfuAI site-compatible linkers 
(see methods), shRNA sequence is introduced at the junctions of the 5' and 3' miR30 sequence (light blue). For shRNAs sub-
cloned from commercially available whole genome libraries [2, 7], fragments can be subcloned to the XhoI/EcoRI sites (dark 
blue) within the 5' and 3' miR30 sequence.BMC Molecular Biology 2007, 8:98 http://www.biomedcentral.com/1471-2199/8/98
Page 5 of 11
(page number not for citation purposes)
Stable expression of multi-miR-shRNA transcripts in a murine macrophage cell line promotes efficient knockdown of endog- enous target genes Figure 3
Stable expression of multi-miR-shRNA transcripts in a murine macrophage cell line promotes efficient knock-
down of endogenous target genes. (a) Architecture of retroviral vectors (FBneo) used to stably express single or double 
miR-shRNAs in RAW264.7 (RAW) macrophages. (b-d) Retroviral expression of miR-shRNA can promote efficient and stable 
knockdown of multiple endogenous target mRNAs; Arrestin 2 and 3 (b), Grk2 and 5 (c) and Pka Cα and Cβ (d) (Data repre-
sent averages (± SEM) from at least 2 independent sample sets). (e) Western blots from Pka Cα and Cβ RAW cell lines dem-
onstrate >95% knockdown of target proteins.BMC Molecular Biology 2007, 8:98 http://www.biomedcentral.com/1471-2199/8/98
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Efficient knockdown of both PKA alpha and beta catalytic subunits is necessary to attenuate PKA-dependent phosphorylation  and transcription Figure 4
Efficient knockdown of both PKA alpha and beta catalytic subunits is necessary to attenuate PKA-dependent 
phosphorylation and transcription. (a) Phosphorylation of the cytoskeletal protein VASP in response to cAMP analogs; 
combined knockdown of Pka Cα and Cβ is required to attenuate phosphorylation in response to either 8Br-cAMP or 8pCPT-
cAMP. (b-e) Induction of PKA-dependent transcripts Nr4a1, Nr4a2, Ctla2α and Ctla2β in response to 8pCPT-cAMP. Induc-
tion of all 4 transcripts is significantly attenuated only upon depletion of both Pka Cα and Cβ (Data represent averages (± SEM) 
from 2 independent experiments).BMC Molecular Biology 2007, 8:98 http://www.biomedcentral.com/1471-2199/8/98
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cAMP effector, such as Epac, could contribute, it seems
more likely that the residual Pka catalytic subunit (Fig.
3d+e) is capable of mediating the residual response. This
observation supports the inherent robustness of this sign-
aling pathway, and is consistent with the finding that the
Pka Cα knockout mice remain viable despite certain cell
types showing <10% of the wild type level of total PKA
activity [16].
Using our multi-miR-shRNA expression platform, we
demonstrate potent knockdown of up to three genes in
transient expression studies (Fig. 1d–f) and three different
pairs of endogenous genes after viral infection of a murine
macrophage cell line (Fig. 3b–e). This approach has great
potential for experimental strategies or clinical applica-
tions requiring depletion of multiple gene targets in cells
with low transduction efficiency. It should be noted how-
ever, that the presence of increasing numbers of miR-
shRNA cassettes in a viral transcript leads to a gradual
reduction in viral titer (see Additional file 2), likely due to
Drosha cleavage of the viral transcript during packaging.
Despite this titer reduction, we were able to achieve viral
titers of >1 × 106 pfu/ml from unconcentrated superna-
tants of lentivirus expressing three miR-shRNAs, well
within the practical range for infection of most intractable
cells.
We engineered the vectors to be extremely versatile with a
high degree of flexibility for downstream applications
(Fig. 5a and Additional file 1). We created the initial
shRNA cloning/testing entry vector with a choice of up to
five interchangeable promoters (CMV, EF1, beta-actin,
ubiquitin-c and MSCV 5'LTR), which can be combined
with six different selection markers upon recombination
to a selection of lentiviral vectors (Fig. 5a). This allows
selection of the optimal promoter for a given cell system;
for example, comparison of MSCV LTR and β-actin pro-
moters driving the Arr2 miR-shRNA in RAW cells shows
the former promotes more potent knockdown (Fig. 5b).
Alternatively, the entry vector promoter can be removed
after shRNA validation for recombination to a variety of
expression platforms with existing promoters. These
include 5'LTR-driven retroviral vectors or CMV/EF1-
driven mammalian expression vectors which can then be
used for creation of stable cell lines. These latter vectors
also contain a broad selection of co-expressed fluorescent
and/or drug selection markers (Additional file 1). Further-
more, the Gateway compatibility of these vectors allows
the miR-shRNA cassettes to be recombined to any appro-
priately configured Gateway-ready expression system.
Conclusion
We have developed an flexible cloning platform for gener-
ation of plasmid vectors and viruses expressing miR-shR-
NAs against multiple target genes. The ability to express
multiple engineered miR-shRNA cassettes from a single
transcript has been previously reported [5,11], and recent
reports have shown that it can also be used to improve
knockdown efficiency by expressing multiple miR-shRNA
against the same target gene [22,23] and to promote
multi-gene knockdown [22-24]. However, Refs.22 and 24
used intron-based expression of miR-shRNA cassettes
from plasmids introduced into easily transfected cell
lines, which is not compatible with the viral based
approaches required with less tractable cell systems. To
our knowledge, our data are the first to demonstrate func-
tional consequences of depleting multiple endogenous
target genes in mammalian cells using miR-shRNA where
multi-gene knockdown is necessary to observe a pheno-
type (Fig. 4). We believe that the versatility of the vectors
we describe here make them a valuable resource to the
research community. Although we clone shRNAs into our
entry vectors using BfuAI compatible linkers, we include
Xho I and Eco RI cloning sites in the flanking miR30
sequence to allow subcloning of miR-shRNAs from popu-
lar whole genome libraries [2,7] into our plasmids (Fig.
2b). Any shRNA subcloned by either of these methods is
then compatible for concatenation in a multi-miR-shRNA
transcript (Fig. 1c).
Availability and requirements
In accordance with the policy of the Alliance for Cellular
Signaling (AfCS), all the vectors described in this study
will be readily available through the American Type Cul-




8-Br-cAMP and 8-pCPT-cAMP were purchased from Cal-
biochem.
Plasmid construction
Entry vectors for cloning miR-shRNA downstream of var-
ious promoters were created by excision of the U6 pro-
moter from the pEN_hUmiRc2 plasmid [11] by SalI digest
and ligation of SalI-flanked PCR products of the β-actin,
CMV, EF1, MSCV LTR and Ubi-c promoters. Cloning of
gene specific miR-shRNA into these entry vectors was by
generation of BfuAI-compatible linkers as described previ-
ously [11]. For the lentiviral destination vectors, the Ubi-
c promoter and GFP cDNA were removed from the
pDSL_hpUG vector (ATCC# 10326371, AfCS#
L06DDLHPUGXA) and replaced with cassettes including
an IRES sequence followed by either GFP, truncated
human CD4, neomycin, hygromycin, puromycin or
zeocin. The pDS_FBneo retroviral destination vector was
created by insertion of an attR site containing Gateway
cassette (Invitrogen) into the multiple cloning site of the
pFB-Neo plasmid (Stratagene). For the FBneo vectors con-BMC Molecular Biology 2007, 8:98 http://www.biomedcentral.com/1471-2199/8/98
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miR-shRNA expression options Figure 5
miR-shRNA expression options. A) Flow chart for expressing miR-shRNA in different expression platforms. Experimental 
details of the various steps are provided in methods. B) Comparison of MSCV LTR and beta actin promoters expressing arres-
tin 2 (Arr2) miR-shRNA or control luciferase (Luc) miR-shRNA in lentivirally infected RAW264.7 macrophages. Constructs 
used for lentivirus production are detailed in Additional file 3.BMC Molecular Biology 2007, 8:98 http://www.biomedcentral.com/1471-2199/8/98
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taining fluorescent proteins, the attR cassette and fluores-
cent protein were subcloned as a single fragment into pFB-
Neo from the mammalian expression plasmids described
below. The FBhyg retroviral vectors were prepared in the
same fashion after excision of the neomycin gene from
pFB-Neo by ClaI/RsrII digest and insertion of the hygro-
mycin resistance cDNA. The CMV promoter-containing
destination vectors for mammalian co-expression of miR-
shRNA with GFP derivatives were created by insertion of
an attR site containing Gateway cassette (Invitrogen) into
the multiple cloning site of the pEGFP-N1, pECFP-N1 and
pEYFP-N1 vectors (Clontech). The pDS_X-mCherry vector
was created in the same fashion from pcDNA-mCherry
(derived from pRSET-B-mCherry, generously provided by
Dr. Roger Tsien, University of California San Diego). The
EF1 promoter versions of the GFP, CFP and YFP constructs
were created in the same way after replacement of the
CMV promoter by EF1 in the initial plasmids. The retrovi-
ral and lentiviral constructs containing various miR-
shRNA (Additional file 3) were all created by LR recombi-
nation as described below.
Cloning and validation of miR-shRNAs
Design and cloning of miR-shRNAs has been described
previously [11]. Briefly, sequences were selected using the
RNAi Codex algorithm [25], with 2–4 independent miR-
shRNAs chosen for each target gene. Gene-specific
sequences were cloned as BfuAI-compatible oligonucle-
otide linkers into the pEN_CmiRc2 vector (Additional
files 1 and 3). The efficacy of the miR-shRNAs was vali-
dated by co-expression with YFP fusions of their cognate
target cDNAs in HEK293 cells as previously described
[26]. The YFP fusion constructs used for these experiments
were obtained from the recently described AfCS plasmid
collection [27]; pEX_EF1_YFP-Arrestin2; AfCS barcode
A08XF063A1TK; atcc id 10374002, pEX_EF1_YFP-Grk2;
AfCS barcode A08XK093A1TK; atcc id 9830392,
pEX_EF1_YFP-Grk5; AfCS barcode A08XK213A1TK; atcc
id 9891141, pEX_EF1_YFP-Gbeta2; AfCS barcode
A08XF075A1TK; atcc id 9891160, pEX_EF1_YFP-PKACa;
AfCS barcode A08XP020A1TK; atcc id 9891081 and
pEX_EF1_YFP-PKACb; AfCS barcode A08XK074A1TK;
atcc id 9830324. The most potent miR-shRNA identified
by this method targeted the following murine sequences:
arrestin 2; TCTCATAGAGCTTGACACCAAT, arrestin 3;
TGCGGCTTATCATCAGAAAGGT, G-protein coupled
receptor kinase 2; ACCGAGGAGAAGTGACCTTTGA, G-
protein coupled receptor kinase 5; AGGCGGCAGCAT-
CAAAGCAATT, G-protein β2; TGCTCATGTATTCCCAC-
GACAA, Pka Cα; AGCCTATCCAGATCTATGAGAA and
Pka Cβ; AAGGTTGTTAAGCTGAAGCAAA.
Creation of constructs with multiple miR-shRNA cassettes
Constructs with multiple miR-shRNA cassettes were cre-
ated by ligating SpeI/PstI fragments containing the desired
downstream shRNA into an XbaI/PstI cut recipient plas-
mid containing the desired upstream shRNA(s) (Fig. 1c).
Loss of the SpeI and XbaI sites permitted cloning of addi-
tional miR-shRNA via the same approach. The resulting
constructs were validated by digestion with BsrGI, which
has recognition sites in the attL1 and attL2 regions.
Subcloning of miR-shRNA cassettes to different expression 
platforms
Constructs were designed to permit subcloning of miR-
shRNA cassettes to different expression platforms by Gate-
way recombination. For lentiviral expression options, this
involved direct LR recombination of the promoter-con-
taining entry vector to any one of six lentiviral destination
vectors with bicistronic expression of different markers or
drug selection genes (Additional files 1 and 3). The desti-
nation vectors for either retroviral or mammalian plasmid
expression have existing promoters, so for these platforms
the promoter was removed from the entry vector prior to
LR recombination. Entry vector promoters were removed
either by BamHI/SpeI or DraI/SpeI digest (see Fig. 2a) and
the vector backbone was religated after treatment with T4
DNA polymerase to flush the DNA termini. Promoter
removal was confirmed in recombinant clones by BsrGI
digest. Retroviral vectors for this study were created by LR
recombination of miR-shRNA cassettes to pDS_FBneo
(Additional files 1 and 3).
Generation of viruses and creation of stable RAW264.7 cell 
lines
Production of lentiviruses and creation of stable lentiviral
RAW cells was carried out as previously described [26].
Retrovirus was generated by transfection of the Phoenix
293T Amphotropic packaging cell line with miR-shRNA-
expressing FBneo retroviral vectors. Briefly, Phoenix cells
were cultured at 37°C, 5% CO2 in 100 mm tissue culture
dishes (Corning) using DMEM (Gibco Invitrogen), 10%
FBS (Gemini), 2 mM glutamine (Gibco Invitrogen), and
100 U/ml Penicillin with 100 µg/ml streptomycin (Gibco
invitrogen). 10 µg per dish of retroviral vector diluted in
Opti-MEM (Gibco Invitrogen) was transfected using Lipo-
fectamine 2000 reagent (Invitrogen). Around 16 hours
post-transfection, the medium on the Phoenix cells was
replaced. Viral supernatant was harvested at 48 hours
post-transfection, spun at 1200 rpm for 5 minutes and fil-
tered through a 0.45 µm filter. Polybrene was added to a
final concentration of 16 µg/ml, and equal volumes of
viral supernantant were placed onto RAW264.7 cells
plated in 6 well tissue culture plates (Corning) 2 hours
prior to virus addition. Final polybrene concentration was
8  µg/ml. The medium on the RAW264.7 cells was
replaced around 16 hours post-infection. 48 hours post-
infection, RAW264.7 cells were re-seeded onto 100 mm
dishes, and infected cells were selected using 500 µg/ml
Geneticin (Gibco Invitrogen).BMC Molecular Biology 2007, 8:98 http://www.biomedcentral.com/1471-2199/8/98
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Assessment of mRNA and protein expression levels
Knockdown of endogenous target mRNA and protein in
stable cell lines was assessed from samples collected at
least 14 days after viral infection, with at least one assess-
ment carried out at >21 days. Detailed procedures for
assessment of mRNA by quantitative real-time PCR (qRT-
PCR) and protein by western blot have been described
previously [26]. Sense and antisense amplification prim-



















ATCG-3', Ctla2α; 5'-TGTGGCTTGACTGGTAAC-3'; 5'-
CAGCATCATTCCTCTCATAC-3', Ctla2β; 5'-GCATTGTCTT
GGGAGTCTTC-3'; 5'-ACAGTGTTGATCTTATATGAGTTC-
3' and the β-actin reference; 5'-TCCATGAAATAAGTGGTT-
ACAGGA-3'; 5'-CAGAAGCAATGCTGTCACCTT-3'; 5'-HE
X-TCCCTCACCCTCCCAAAAGCCACC-BHQ1-3'. The fol-
lowing antisera were used; anti-YFP (BD Clontech #8371-
2), anti-Pka Cα (Cell Signaling Technology, #4782), anti-
Pka Cβ (Santa Cruz Biotechnology, sc-904) and Arr2
(A1CT #140; generously provided by Dr. Robert Lefkow-
itz, Duke University).
Phosphoprotein detection by western blot
A detailed protocol for detection of phosphoproteins in
extracts from stimulated RAW cells can be found on the
AfCS website [28] (PP00000177 and PP00000181). Fol-
lowing this protocol, RAW cells were stimulated for 10
min with 100 µM 8Br-cAMP or 8pCPT-cAMP, and phos-
pho-VASP levels were assessed using an antibody from
Cell Signaling Technology (#3111).
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